New York, NY (PRWEB) January 18, 2013
The prescription drug resource center DrugRisk.com has added new information for those patients using the vaginal ring contraceptive NuvaRing showing, while the device has been linked to blood clots in the past, the risk may be even higher for women suffering migraines.
The mission of DrugRisk is to improve patient safety through education, including the latest drug warnings, recalls, studies and litigation news. “While several studies have linked NuvaRing to blood clots, this is the first we’ve seen that suggests women with migraines may be at a higher risk,” explains DrugRisk representative Ryan Mayer.
DrugRisk previously added warnings from experts linking vaginal rings like NuvaRing to higher blood clot risks than traditional birth control pills, but there still has been no NuvaRing recall.
The British Medical Journal published a Danish study on May 10, 2012 linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives. On June 14, 2012, the New England Journal of Medicine also published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.
Now, information added to the site shows researchers at Brigham and Women’s Faulkner Hospital in Boston found that, while combined hormone vaginal ring contraceptives like NuvaRing can increase blood clot risks for all women, the risks are significantly higher for those suffering migraines.*
DrugRisk has learned that, due to the number of patients filing NuvaRing lawsuits over blood clots, cases have been consolidated to a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.
The latest NuvaRing legal news added to the site shows the number of NuvaRing lawsuits filed over blood clots has risen by nearly 5% to 1076 from the last report, according to the U.S. Judicial Panel on MultiDistrict Litigation.**
Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.
Due to the specialized nature of federal MDL drug injury cases, the DrugRisk Center only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
For more information on the research, side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.